[{"id":"08f1577b-f4e1-45d7-b284-738f722043fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT05212922","created_at":"2022-01-29T18:05:38.643Z","updated_at":"2024-07-02T16:35:52.926Z","phase":"Phase 2","brief_title":"A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC","source_id_and_acronym":"NCT05212922","lead_sponsor":"Eucure (Beijing) Biopharma Co., Ltd","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • YH001"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-03-20"}]